Cytek Biosciences, Inc. reports recurring developments in cell analysis instruments, reagents, services, and financial performance. The company uses patented Full Spectrum Profiling™ (FSP®) technology to analyze fluorescence signals in flow cytometry and related cell analysis workflows.
News about Cytek Biosciences commonly covers earnings releases, revenue trends, recurring service and reagent revenue, instrument placements, product platforms such as Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS, Cytek Aurora™ Evo, Cytek Orion™, ESP™ detection technology, and Amnis® and Guava® products, as well as investor conference participation and business outlook updates.
Cytek Biosciences (CTKB) announced the addition of Cloud Analysis to its Cytek Cloud platform on September 23, 2026.
The tool imports experimental data directly from SpectroFlo desktop software, allowing researchers to continue analysis where they left off. It also provides online storage and access from a Mac or PC. Cytek Cloud has more than 28,000 users and double-digit year-over-year user growth.
Cytek also introduced a Premium subscription tier that adds Cloud Analysis and online storage to Pro features. Premium and the new analysis tool are currently available only in the U.S. The Basic plan provides core tools at no cost.
Cytek Biosciences (CTKB) and Sysmex Europe announced a strategic collaboration across more than a dozen European countries to enhance clinical flow cytometry workflows. The partners aim to provide laboratories with an integrated, end-to-end solution spanning automated sample preparation, routine testing and advanced multi-color spectral analysis. Sysmex contributes its clinical flow portfolio, including the XF-1600 flow cytometer and PS-10 automated sample preparation system, while Cytek adds its Northern Lights™-CLC spectral flow cytometer. The combined offering targets complex applications such as leukemia, lymphoma and measurable residual disease assessment.
Cytek Biosciences (CTKB) will highlight its spectral flow cytometry solutions and Full Spectrum Profiling™ (FSP®) technology at the ESCCA 2026 Conference and ICCS 2026 meeting this fall. These events focus on clinical cytometry applications across hematology, immunology, oncology, and broader clinical research.
Cytek’s spectral technology captures the full spectrum of fluorescent signals, allowing laboratories to design more complex panels, streamline workflows, and gain deeper insights from each sample. More than 4,200 peer-reviewed publications have cited Cytek FSP systems, underscoring their use in cell biology, immunology, oncology, and clinical research.
At ESCCA 2026 in Salzburg, Austria (September 9–12), Cytek will exhibit at Booth PL2 and host an Industrial Partner Presentation on September 11 at 12:15 p.m., led by Mikael Roussel, M.D., Ph.D., on the use of spectral cytometry in routine diagnostics and minimal residual disease (MRD) monitoring. At ICCS 2026 in Miami, Florida (October 2–6), Cytek will exhibit at Booths 100/101 and host a Corporate Workshop on October 4 at 2:00 p.m., as well as KOL dinners at both meetings.
Cytek Biosciences (Nasdaq: CTKB) announced participation in three upcoming healthcare investor conferences in September 2026. The company will attend the Wells Fargo 21st Annual Healthcare Conference on September 8, the Morgan Stanley 24th Annual Global Healthcare Conference with a fireside chat on September 16, and Deutsche Bank’s 2026 Healthcare Summit on September 17.
According to Cytek Biosciences, CEO Wenbin Jiang and CFO William McCombe will join select sessions, and a live and archived webcast of the Morgan Stanley fireside chat will be available via the investors section of the company’s website.
Cytek Biosciences (Nasdaq: CTKB) reported that a Delaware jury returned a mixed verdict in a patent infringement case brought by Beckman Coulter. The jury found in Cytek’s favor on three of four asserted patent claims, determining noninfringement and invalidity for those claims.
For the remaining claim, the jury found no literal infringement but concluded infringement under the doctrine of equivalents and awarded past damages of $20 million in lost profits and $36 million in royalties. Cytek plans post-verdict motions to challenge this finding and the damages, and stated that the verdict does not require changes to its current products, which remain available worldwide.
Cytek Biosciences (Nasdaq: CTKB) reported second quarter 2026 revenue of $48.1 million, up 6% year over year, driven by instrument growth in the U.S. and China and higher service revenue. GAAP gross profit rose 19% to $28.3 million, with gross margin improving to 59% (53% excluding a one-time tariff refund). Non-GAAP adjusted gross margin was 61% (56% excluding the refund).
Total recurring revenue reached $18.5 million, and on a trailing 12‑month basis represented 35% of total revenue, up from 32% a year earlier. The installed base expanded to 3,933 instruments, adding 142 units in the quarter. Operating expenses rose 15% to $39.7 million, including higher R&D, sales and marketing, and a 24% increase in G&A tied to litigation-related expenses, severance and personnel costs. Net loss widened to $12.2 million, or $0.09 per share, versus $5.6 million a year ago, and adjusted EBITDA shifted to a $1.5 million loss.
Cash, cash equivalents and marketable securities totaled $262.0 million at June 30, 2026. Cytek launched the Cytek Borealis 7‑laser full spectrum flow cytometer and new Cytek Aurora Evo configurations. The company updated 2026 revenue guidance to $207–$212 million, raising the midpoint by $1 million, assuming unchanged foreign exchange rates.
Cytek Biosciences (Nasdaq: CTKB) announced it will report its second quarter 2026 financial results after market close on Wednesday, August 5, 2026. Management will host a webcast conference call at 1:30 p.m. Pacific / 4:30 p.m. Eastern to discuss results, business developments and outlook, accessible via the Investors section of its website at investors.cytekbio.com.
Cytek Biosciences (Nasdaq: CTKB) has opened a new innovation center in Bellevue, Washington, relocating its prior Seattle-area operations to a dedicated facility focused on research and development, customer engagement, and technical training. The company is the sole tenant and has consolidated key functions under one roof.
The Bellevue site includes R&D laboratories, instrument service training and customer demonstration areas, and assembly and testing operations. According to Cytek, the center is a strategic infrastructure investment intended to foster collaboration, accelerate product development, and support solutions for evolving needs in research and clinical applications, including high-dimensional cell analysis.
Cytek Biosciences (Nasdaq: CTKB) will participate in Singular Research’s Las Vegas Invitational Conference, held June 14-16, 2026. Cytek management is scheduled to present on Monday, June 15, 2026, at 11:00 a.m. Pacific Time.
A live and archived webcast will be available on the company’s investor website.
Cytek Biosciences (Nasdaq: CTKB) will showcase major spectral flow cytometry innovations at CYTO 2026 in West Palm Beach, June 6–10, 2026. Highlights include the first public debut of the 7-laser Cytek Borealis system and new automation‑ready Cytek Aurora Evo configurations.